GlassScriptPhysician profile
Kean T Oh
NPI 1780686485
$1,178.38
in general payments reported to CMS, 2019-2025
10 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $103 · 2021: $511 · 2022: $325.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alimera Sciences, INC. | $767.94 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $127.57 | 2019-2020 | |
| Allergan, INC. | $126.22 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $83.99 | 2019-2022 | |
| Eyepoint US, INC. | $34.62 | 2019-2021 | |
| Abbvie INC. | $14.66 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $11.98 | 2019 | |
| Mallinckrodt Hospital Products INC. | $11.40 | 2021 |
2 companies reported research payments only; those appear in the research section below.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kean Oh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.